Tesaro's Varubi: Safety, Dosing Convenience Could Drive Third NK-1 Inhibitor
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approval for prevention of chemotherapy induced nausea and vomiting in delayed phase after chemo paves way for fourth-quarter market entry.